

Handbook of Neurochemistry

SECOND EDITION

Volume 7

**STRUCTURAL ELEMENTS OF
THE NERVOUS SYSTEM**

Edited by

Abel Lajtha

Handbook of
Neurochemistry

SECOND EDITION

Volume 7

**STRUCTURAL ELEMENTS OF
THE NERVOUS SYSTEM**

PLENUM PRESS • NEW YORK AND LONDON

Contributors

Harish C. Agrawal, Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri 63178

Gérard Alonso, Laboratoire de Neuroendocrinologie, Université de Montpellier II, 34100 Montpellier, France

Joyce A. Benjamins, Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan 48201

A. Lorris Betz, Departments of Pediatrics and Neurology, University of Michigan, Ann Arbor, Michigan 48109

Elisabeth Bock, The Protein Laboratory, Sigurdsgade 34, Denmark

J. B. Clark, Department of Biochemistry, The Medical College of St. Bartholomews Hospital, University of London, London EC1M 6BQ, England

George H. DeVries, Department of Biochemistry, Medical College of Virginia, Richmond, Virginia 23298

M. Saïd Ghandour, Centre de Neurochimie du CNRS, 67084 Strasbourg, France

Gary W. Goldstein, Departments of Pediatrics and Neurology, University of Michigan, Ann Arbor, Michigan 48109

Giorgio Gombos, Centre de Neurochimie du CNRS, 67084 Strasbourg, France

Boyd K. Hartman, Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri 63178

Richard L. Klein, Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi 39216

Jack D. Klingman, Department of Biochemistry, School of Medicine, State University of New York at Buffalo, Buffalo, New York 14214

Edward Koenig, Division of Neurobiology/Department of Physiology, State University of New York at Buffalo, Buffalo, New York 14214

Harold Koenig, Neurology Service, Veterans Administration Lakeside Medical Center; and Department of Neurology, Northwestern University Medical School, Chicago, Illinois 60611

O. Keith Langley, Centre de Neurochimie du CNRS, 67084 Strasbourg, France

Kathryn Mack, Laboratory of Cell Biology, Institute for Basic Research in Developmental Disabilities, Staten Island, New York 10314

Henry R. Mahler, deceased. Department of Chemistry and Cellular, Developmental and Molecular Biology Program, Indiana University, Bloomington, Indiana 47405

Charles A. Marotta, Molecular Neurobiology Laboratory of the Laboratories for Psychiatric Research, Mailman Research Center, McLean Hospital, Belmont, Massachusetts 02178; and the Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02115

Marilyn W. McCaman, Division of Neurosciences, Beckman Research Institute of the City of Hope, Duarte, California 91010

Pierre Morell, Department of Biochemistry, University of North Carolina, Chapel Hill, North Carolina 27514

W. J. Nicklas, Department of Neurology, University of Medicine and Dentistry of New Jersey, Rutgers Medical School, Piscataway, New Jersey 08854

William H. Oldendorf, Veterans Administration Medical Center, Los Angeles, California 90073; and Departments of Neurology and Psychiatry, University of California, Los Angeles, School of Medicine, Los Angeles, California 90024

David Soifer, Laboratory of Cell Biology, Institute for Basic Research in Developmental Disabilities, Staten Island, New York 10314

Maria Spatz, Laboratory of Neuropathology and Neuroanatomical Sciences, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Public Health Service, U.S. Department of Health and Human Services, Bethesda, Maryland 20205

Yasuo Takahashi, Department of Neuropharmacology, Brain Research Institute, Niigata University, Niigata 951, Japan

Åsa K. Thureson-Klein, Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi 39216

V. P. Whittaker, Abteilung Neurochemie, Max-Planck-Institut für Biophysikalische Chemie, Göttingen, Federal Republic of Germany

Foreword

Neurochemistry, having the objective of elucidating biochemical processes subserving nervous activity, emerged as an application of chemistry to the investigation of neurobiological problems as a post-World War II phenomenon. However, only in the last 40 years has the chemical community recognized neurochemistry as a distinct, if hybrid, discipline. During this period great strides have been made. However, recently neurochemistry, along with neurophysiology, neuropharmacology, neuroanatomy, and the behavioral sciences, has emerged to form *neuroscience*, a new community of scientists with its own national society, journals, and meetings. Actually, this recently formed hybrid, neuroscience, is in the process of merging with another well-established discipline, molecular genetics (frequently called molecular biology, and itself a hybrid), which appears to have sufficient hybrid vigor to form yet a new community of scientists, which, for want of a more imaginative term, has been called *molecular genetic neuroscience*.

Clearly, advantages resulting from such mergers or hybridizations accrue not only from the merging discipline (neurochemistry in this case) to the new community (molecular genetic neuroscience), but also in the reverse direction. This Foreword will be concerned primarily with examples of this latter process.

Among the first products of the new dispensation was the invention and development of biochemical technologies that have greatly facilitated research in this field. Complex equipment made its appearance academically and commercially early on, such as "gene machines" for nucleotide sequence analysis and synthesis of DNA. Submicrogram quantities of particular proteins (identified by monoclonal antibodies or two-dimensional electrophoresis) sufficed to determine, and even isolate, the gene or genes that synthesize the protein. With such equipment it is possible to pass from phenotype (e.g., a microgram or less of purified protein) to genotype (expressed as the nucleotide sequence of DNA). Similarly, it is possible to pass from genotype to phenotype. A method has recently been published indicating how, from cDNA clones, it is possible to determine nucleotide sequences, hence amino acid sequences, of protein encoded by brain-specific mRNAs. Antisera to corresponding proteins are used immunocytochemically to localize the protein in the brain. Such proteins may serve as markers for novel neuronal pathways and transmitters used in pathways.

With conventional neurochemical methods it has, over the years, been possible to discover but a small number (circa several dozen) of brain-specific proteins. However, by application of the new technologies, evidence has been obtained for the existence of many thousands of different brain-specific proteins. Many of these proteins may occur very sparsely in the brain, but in the subpopulations of cell types they may occur in high-copy amounts and may play a significant role.

In addition to the approximately ten classical small-molecule transmitters, a large and rapidly growing list of putative peptidergic transmitters or modulators of neurotransmitters has been identified and chemically characterized by application of the new technology, as have other substances of high neurobiological activity (e.g., peptides, receptors, hormones, and factors). Clearly a large flood of new compounds will soon be appearing in the literature, forming a handsome grist for neurochemical study and for function determination.

Neurochemistry will, in the next decade, doubtless pass through a historic transition, which may spin off new communities of scientists with new opportunities for scientific discovery and valuable biomedical application.

Francis O. Schmitt

Contents

Chapter 1

The Synaptosome

V. P. Whittaker

1. Introduction	1
2. Methods for Preparing Brain Synaptosomes	3
2.1. Homogenization of Tissue	3
2.2. Separation of Synaptosomes from Other Subcellular Particles	6
2.3. Evaluation of Fractions	8
2.4. Atypical Brain Synaptosomes	15
3. The Preparation of Synaptosomes from Peripheral Tissues	16
4. Subfractionation of Synaptosomes into Their Component Organelles	17
4.1. Disruption of Synaptosomes	17
4.2. Fractionation of Osmotically Lysed Synaptosomes	19
4.3. Separation of Postsynaptic Membranes	21
5. The Synaptosomes as a Functional Entity	22
5.1. The Synaptosome as a Miniature Cell	22
5.2. The Synaptosome as a Surviving Presynaptic Nerve Terminal	23
6. Some Limitations and Future Developments in Synaptosome Technology	31
References	31

Chapter 2

The Synaptic Vesicle

V. P. Whittaker

1. Introduction	37
2. Isolation	38
2.1. Mammalian Synaptic Vesicles	38
2.2. Vesicles from <i>Torpedo</i> Electromotor Nerve Terminals	40

2.3. Vesicles from Squid Optic Lobes	48
3. Vesicle Composition	48
3.1. Vesicles Derived from Mammalian Central and Peripheral Synapses	48
3.2. <i>Torpedo</i> Vesicles	51
4. Vesicle Recycling and Metabolic Heterogeneity	56
4.1. The Preferential Release of Newly Synthesized Transmitter and the Concept of Vesicle Metabolic Heterogeneity	56
4.2. The Use of False Transmitters	59
4.3. Immunohistochemical Evidence for Vesicle Exo- and Endocytosis	59
4.4. The Cytoplasmic Theory of Transmitter Release	61
5. The Life Cycle of the Synaptic Vesicle	62
5.1. Genesis and Axonal Transport	62
5.2. Exo- and Endocytosis	63
6. Future Perspectives	64
References	65

Chapter 3

Noradrenergic Vesicles: Molecular Organization and Function

Richard L. Klein and Åsa K. Thureson-Klein

1. Noradrenergic Vesicles: Occurrence and Formation	71
1.1. Large Dense-Cored Vesicles	71
1.2. Small Dense-Cored Vesicles	71
1.3. Percentages of LDVs and SDVs in Different Noradrenergic Terminals: An Interpretation	73
2. Purified Fractions of Noradrenergic Vesicles	77
2.1. Large Dense-Cored Vesicles of 80–90% Purity	77
2.2. Small Dense-Cored Vesicles of 25–40% Purity	78
2.3. Comments on Vesicle Purity Estimates	78
3. Axoplasmic Transport of Newly Formed Large Dense-Cored Vesicles	80
3.1. A Unique Method to Study Aspects of Axoplasmic Transport	80
3.2. Establishment of a Fast-Release Pool of NE: A Compositional and Functional Change	81
3.3. Changes in NE:ATP Ratios and Implications for the Role of ATP	81
4. Neuronal Subcellular Localization of Dopamine β -Hydroxylase and the Origin of Circulating Enzyme	82
4.1. The Problem and the Hypothesis	82
4.2. Dopamine β -Hydroxylase in LDVs	82
4.3. Evidence for Dopamine β -Hydroxylase in SDVs?	83
4.4. Comparisons with Bovine Adrenal Chromaffin Granules	85

5. Coexistence of Neurotransmitter and Neuropeptide	85
5.1. Coexistence at the Cell Level	85
5.2. Coexistence at the Vesicle Level	85
5.3. Peptides Are Stored Only in Large-Type Dense-Cored Vesicles: A Tentative Generalization	90
6. Glycoprotein and Glycosaminoglycan Contents of Large Dense- Cored Vesicles Compared to Chromaffin Granules	91
7. Lipid Content of Noradrenergic Large Dense-Cored Vesicles Compared to Chromaffin Granules	92
8. Binding of Cytoplasmic Proteins to Vesicles	92
8.1. Calmodulin Binding to LDVs	93
8.2. Protein I Binding to LDVs or an Endogenous Constituent?	93
8.3. Tubulin Binding to LDVs	94
8.4. Actin Binding to Neuronal Vesicles	94
9. Transport Systems	94
9.1. H^+ -Translocating Mg^{2+} -ATPase	94
9.2. Norepinephrine Synthesis from Dopamine	96
10. Exocytosis: Biochemical, Physiological, and Ultrastructural Evidence	98
10.1. Potential for Exocytotic Release of Soluble Contents	98
10.2. Ultrastructural Evidence for Exocytosis from Noradrenergic Terminals: A Human Blood Vessel Model	101
References	107

Chapter 4

Synaptic Proteins

Henry R. Mahler

1. Introduction	111
2. Methodological Aspects	112
2.1. Criteria for Inclusion	112
2.2. Isolation and Characterization of Synaptic and Subsynaptic Membranes	115
3. Protein Constituents of Synaptic Membranes	117
3.1. General Considerations	117
3.2. Filamentous Proteins	118
3.3. Calcium-Binding Proteins	121
3.4. Glycoproteins	124
3.5. Protein Kinases and Phosphoproteins	125
3.6. Proteins Involved in Transmitter Function	127
3.7. Synaptic Antigens	129
3.8. Synaptic Vesicle Proteins	130
4. Outlook	131
References	131

Chapter 5**Brain Mitochondria***J. B. Clark and W. J. Nicklas*

1. Introduction	135
2. Preparation and Properties of Brain Mitochondria	135
2.1. Preparative Techniques	135
2.2. Properties of Brain Mitochondria	140
3. Integrated Metabolism of Intact Brain Mitochondria	146
3.1. Introduction	146
3.2. Pyruvate and Ketone Body Metabolism	147
3.3. Glutamate Transport, Metabolism, and Synthesis	149
3.4. Transport and Metabolism of 4-Aminobutyrate (GABA)	150
3.5. Mitochondrial/Cytosolic Transport Systems	150
3.6. Calcium Transport in Brain Mitochondria	152
4. Developmental and Aging Studies on Brain Mitochondria	152
4.1. Developmental Studies	152
4.2. Aging Studies	155
5. Neuropathological Studies with Brain Mitochondria	156
References	156

Chapter 6**The Smooth Endoplasmic Reticulum***Gérard Alonso*

1. Introduction	161
2. Structural Organization of Axonal Smooth Endoplasmic Reticulum	162
2.1. Three-Dimensional Organization of Axonal Smooth Endoplasmic Reticulum	162
2.2. Relationships between Axonal Smooth Endoplasmic Reticulum and Other Axonal Structures	163
3. Smooth Endoplasmic Reticulum and Axonal Transport	164
3.1. Evidence for Smooth Endoplasmic Reticulum Participation in Axonal Transport	165
3.2. Nature and Role of Materials Transported by Axonal Smooth Endoplasmic Reticulum	165
3.3. Heterogeneity of the Axonal Smooth Endoplasmic Reticulum	169
3.4. Mechanisms of Axonal Smooth Endoplasmic Reticulum Transport	172
4. Conclusions	173
References	173

Contents

Chapter 7

Lysosomes

Harold Koenig

1. Introduction	177
2. Lysosomal Enzymes	177
2.1. Biochemical Composition	177
2.2. Biosynthesis of Lysosomal Enzymes	178
2.3. Role of Mannose-6-Phosphate Recognition Marker	180
2.4. Disease- and Drug-Induced Defects in Lysosomal Enzyme Processing	181
2.5. Physicochemical Modifications of Lysosomal Enzymes during Intracellular Transport	181
2.6. Synthesis and Turnover of Lysosomal Glycoproteins in Relation to pIs	182
3. Lysosomal Lipoglycoproteins	183
4. Endocytosis	184
4.1. Types of Endocytosis	184
4.2. Receptor-Mediated Endocytosis	185
4.3. Cell Regulation of Endocytosis	186
5. Autophagy	187
5.1. Role of Lysosomal Autophagy in Intracellular Protein Degradation	187
5.2. Hormonal Regulation of Lysosome-Mediated Protein Degradation	190
5.3. Lysosome-Mediated Protein Degradation in Muscle Pathology	191
5.4. Molecular and Cellular Regulation of Lysosomal Proteolysis	192
6. Lysosomal Storage Disorders	196
6.1. Endogenous Lysosomal Storage	197
6.2. Lysosomal Storage Induced by Exogenous Agents	197
References	200

Chapter 8

Brain Nuclei

Yasuo Takahashi

1. Introduction	205
2. Isolation of Nuclei	205
3. Brain Nucleolus	206
4. Chromatin Analysis	209
5. Nuclear Components	212
6. RNA Synthesis	217
7. DNA Synthesis	220
8. Protein Synthesis and Other Enzymes	222

9. Receptor Activity	224
10. Conclusion	225
References	226

Chapter 9

Membrane Markers of the Nervous System

Elisabeth Bock

1. Introduction	231
2. Neuronal Surface Markers	232
2.1. Neuronal Plasma Membrane Markers	232
2.2. Retinal Cell Membrane Markers	237
2.3. Markers of the Synapse	238
3. Glial Surface Markers	240
3.1. NS-1: An Oligodendroglial Marker	240
3.2. Ran-1: A Schwann Cell Marker	241
3.3. Ran-2	241
3.4. Other Glial Membrane Markers Defined by Monoclonal Antibodies	241
References	242

Chapter 10

Microtubules in the Nervous System

David Soifer and Kathryn Mack

1. Introduction	245
2. Microtubules in Nervous Tissue	246
2.1. Distribution in Neurons	246
2.2. Distribution in Glia	249
3. The Composition and Structure of Microtubules	249
3.1. Proteins	249
3.2. Structural Elements	250
4. Microtubule Assembly	251
4.1. Preparation of Assembly-Competent Tubulin	252
4.2. Microtubule Elongation and Assembly	253
5. Microtubule-Associated Proteins	264
5.1. Distribution in the Nervous System	264
5.2. Reactions with Tubulin	266
5.3. Cold-Stable Microtubules	268
6. Expression of Tubulin Genes	268
6.1. Multiple Forms of Tubulin	268
6.2. Regulation of Synthesis of Microtubule Proteins	269
7. Biosynthesis and Processing of Microtubule Proteins	270
7.1. Free versus Membrane-Bound Polyribosomes	270

7.2. Membrane-Associated Tubulin	271
7.3. Microtubule-Associated Protein Kinases	271
8. Relationships between Microtubule Proteins and Other Components of the Neuronal Cytoskeleton	272
8.1. Interactions with Neurofilaments	272
8.2. Interactions with Actin	273
9. Closing Remarks	273
References	273

Chapter 11

Neuronal Intermediate Filaments

Charles A. Marotta

1. Introduction	281
2. Neurofilaments Compared with Other Intermediate Filaments	281
3. Distribution, Morphology, and Fine Structure	283
4. Purification	284
5. Properties of Isolated Neurofilament Proteins	288
5.1. Evidence That the Triplet Proteins are Constituents of Neurofilaments	288
5.2. Characteristics of the Isolated Proteins	288
5.3. Peptide Mapping and Amino Acid Composition	291
5.4. Reassembly into Filaments	292
5.5. Interaction with Microtubule Protein	294
6. Immunologic Studies	295
7. Metabolism	300
7.1. Synthesis	300
7.2. Phosphorylation	301
7.3. Degradation	303
8. Neurofibrillary Tangles	305
References	309

Chapter 12

Local Synthesis of Axonal Protein

Edward Koenig

1. Background	315
1.1. Introduction	315
1.2. Major Axonal Proteins	316
1.3. Metabolic Stability of Slowly Transported Polypeptides	317
2. Axonal RNA	320
2.1. Morphological Evidence of Ribosomes	320
2.2. Analysis of Axonal RNA	321
2.3. Sources of Axonal RNA	322

3. Local Synthesis of Axonal Proteins	326
3.1. Early Evidence of Local Protein Synthesis	326
3.2. Effects of Nerve Injury	327
3.3. Local Synthesis in Axons Regenerating in Tissue Culture	328
3.4. Polypeptides Labeled in Mammalian Axons	329
4. Sheath Cells as a Source of Axonal Proteins	331
5. Possible Significance of Local Synthesis for Toxic Axonopathies	334
6. Possible Significance of Local Synthesis of Axonal Proteins	335
References	337

Chapter 13

The Axonal Plasma Membrane

George H. DeVries

1. Introduction	341
1.1. Definition of Axonal Plasma Membrane	341
1.2. Scope of the Chapter	341
2. Preparation of Axolemma-Enriched Fractions from Nervous Tissue	342
2.1. Axolemma-Enriched Fractions Derived from Invertebrate Unmyelinated Axons	342
2.2. Axolemma-Enriched Fractions Derived from Vertebrate Myelinated Axons	346
2.3. Axolemma-Enriched Fractions Derived from Cultured Unmyelinated Axons	346
3. Proteins of Axolemma-Enriched Preparations	347
3.1. Enzymes	347
3.2. Other Metabolic Functions Associated with the Axonal Plasma Membrane	349
3.3. Molecular Weight Profile of Proteins	351
4. Sodium Channels in Axolemma-Enriched Preparations	353
5. Acetylcholine-Binding Macromolecule in Axonal Membrane Preparations	354
6. Lipids of Axolemma-Enriched Preparations	354
6.1. Phospholipids	354
6.2. Cholesterol	356
6.3. Glycolipids	356
7. Conclusions	357
7.1. Summary of Common Properties of Axonal Plasma Membrane Preparations	357
7.2. Future Directions for Defining the Molecular Properties of the Axonal Plasma Membrane	357
References	359

Chapter 14**Central Nervous System Myelin**

*Joyce A. Benjamins, Pierre Morell, Boyd K. Hartman,
and Harish C. Agrawal*

1. Introduction: Structure and Function of Myelin	361
2. Isolation of Myelin	361
3. Proteins of CNS Myelin	362
3.1. Composition	362
3.2. Extraction and Purification	368
3.3. Properties of Myelin Proteins	368
3.4. Metabolism of Myelin Proteins	377
4. Lipids of CNS Myelin	380
4.1. Chemical Studies	380
4.2. Metabolism of Myelin Lipids	384
5. Intracellular Processing of Myelin Components	391
5.1. Current Models	391
5.2. Immunohistochemical Localization of Myelin Proteins and Lipids	392
5.3. Kinetics of Assembly and Turnover	398
5.4. Myelin Subfractions and Precursor Membranes	402
6. Summary	405
References	405

Chapter 15**Autonomic Ganglia and Their Biochemistry**

Jack D. Klingman

1. Introduction	417
2. Embryology	418
3. Anatomic Physiology	420
4. Trophic Factors	422
4.1. Ontogeny and Phenotypic Expression; Nerve Growth Factor	422
4.2. Other Survival, Maintenance, and Phenotypic Agents	424
4.3. To Be or Not to Be: Phenotypic Transmitter Expression	425
5. Other Transmitters	432
5.1. γ -Aminobutyric Acid	432
5.2. Substance P	432
5.3. Enkephalins	432
5.4. LHRH-like Peptides	432
6. Destruction of Sympathetic Ganglia	434
7. Metabolism	434
7.1. Oxygen	437
7.2. Glucose	438

7.3. Glycogen	438
8. Stimulation; Metabolism	439
8.1. Glucose	439
8.2. Glucose Lack	440
8.3. Alternate Substrates	441
8.4. CO ₂ and Hexose Monophosphate Shunt	441
8.5. Amino Acids	443
8.6. Proteins	448
8.7. RNA and Protein	448
8.8. Lipids	449
8.9. Cyclic AMP	456
8.10. Cyclic GMP	456
9. Immunology	457
References	458

Chapter 16

Brain Capillaries: Structure and Function

A. Lorris Betz and Gary W. Goldstein

1. Introduction	465
2. Structure	465
2.1. Endothelial Cell	465
2.2. Pericyte	468
2.3. Basement Membrane	469
2.4. Relationship to Astrocytes and Neurons	469
3. Metabolism and Transport	470
3.1. Energy Substrates	470
3.2. Glucose Transport	470
3.3. Amino Acid Transport	471
3.4. Potassium Transport	472
3.5. Neurotransmitter Metabolism	473
3.6. Receptors and Adenylate Cyclase	474
3.7. Prostaglandins	475
4. Culture of Endothelial Cells	476
4.1. Cell Identification	477
4.2. Culture Methods	478
5. Conclusions	480
References	480

Chapter 17

The Blood-Brain Barrier

William H. Oldendorf

1. Introduction	485
---------------------------	-----